Lefebvre Juliette, Cherifi Aboubaker, Hossu Gabriela, Fijean Anne-Laure, Morel Olivier, Bertholdt Charline, Beaumont Marine, Dap Matthieu
Department of Obstetrics and Fetal Medicine, Nancy University Hospital, Nancy, France.
IADI INSERM-U1254, Nancy University Hospital, Vandœuvre-lès-Nancy, France.
BMJ Open. 2025 Aug 10;15(8):e093090. doi: 10.1136/bmjopen-2024-093090.
Pre-eclampsia and fetal growth restriction (FGR) are two principal complications of pregnancy related to placental dysfunction. Nevertheless, knowledge of the underlying pathophysiological mechanisms remains inadequate, and only a few tools are available for in vivo assessment of placental perfusion. Contrast-enhanced ultrasound (CEUS) allows organ vascularisation evaluation via a strictly intravascular gas microbubble. The primary aim of this study is to compare placental vascularisation parameters obtained via CEUS between pregnancies with FGR and those without FGR.
This is a single-centre, prospective, comparative, non-randomised, feasible, open and interventional study. We will include 30 women with medical termination of pregnancy divided into two groups: one with severe FGR and the other without FGR. Severe FGR is defined as an estimated fetal weight below the third percentile for gestational age. Women will be informed and recruited in the fetal medicine unit over a period of 48 months. The primary goal of this study is to compare the placental contrast ultrasound parameter measurements according to group. The primary objective is to compare placental contrast ultrasound data in women who undergo medical termination of pregnancy at a gestational age of 16 weeks (38+6 days) between two groups: a group with FGR and a group without FGR. The secondary objectives are as follows: (1) to describe the placental vascularisation parameters measured by CEUS; (2) to describe the parameters for quantifying vascularisation at different gestational ages via CEUS; (3) to study the associations between CEUS data and placental histological data and (4) to establish a biological collection of placentas to increase our knowledge of the development and functions of the placenta during pregnancy. The statistical analysis will include descriptive analysis for all study patients, with quantitative data described by means±SDs, medians, IQRs, and extreme values and qualitative data reported as counts and percentages. Comparisons of placental contrast ultrasound parameters between the two groups will be performed via Student's t-test or the Mann-Whitney U test on the basis of data normality. Associations between CEUS parameters and placental histology data will be analysed with Spearman or Pearson correlations. Qualitative associations will be studied via analysis of variance or the Kruskal-Wallis test. Box plot representations will be used when applicable. Analyses will be performed with R software, with significance set at p<0.05.
This study was approved by the French Ethics Committee, the CPP (Comité de Protection des Personnes) SUD EST II - LYON - FRANCE, on 26 April 2024, with reference number 2023-506936-34-00, and the competent authority ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé) authorised the study on 17 May 2024. The results of this study will be published in a peer-reviewed journal and will be presented at relevant conferences.
NCT06497959; EU CT number: 2023-506936-34-00.
子痫前期和胎儿生长受限(FGR)是与胎盘功能障碍相关的两种主要妊娠并发症。然而,对其潜在病理生理机制的了解仍然不足,并且仅有少数工具可用于胎盘灌注的体内评估。超声造影(CEUS)可通过严格的血管内气体微泡评估器官血管化。本研究的主要目的是比较通过CEUS获得的FGR妊娠与非FGR妊娠的胎盘血管化参数。
这是一项单中心、前瞻性、比较性、非随机、可行、开放性和干预性研究。我们将纳入30例接受人工流产的女性,分为两组:一组为重度FGR,另一组为非FGR。重度FGR定义为估计胎儿体重低于孕周的第3百分位数。将在48个月内于胎儿医学科告知并招募女性。本研究主要目的是根据分组比较胎盘超声造影参数测量值。主要目标是比较两组在孕16周(38 + 6天)接受人工流产的女性的胎盘超声造影数据:一组为FGR组,另一组为非FGR组。次要目标如下:(1)描述通过CEUS测量的胎盘血管化参数;(2)描述通过CEUS量化不同孕周血管化的参数;(3)研究CEUS数据与胎盘组织学数据之间的关联;(4)建立胎盘生物样本库以增加我们对孕期胎盘发育和功能的了解。统计分析将包括对所有研究患者的描述性分析,定量数据用均值±标准差、中位数、四分位数间距和极值描述,定性数据以计数和百分比报告。两组间胎盘超声造影参数的比较将根据数据正态性通过Student's t检验或Mann-Whitney U检验进行。CEUS参数与胎盘组织学数据之间的关联将用Spearman或Pearson相关性分析。定性关联将通过方差分析或Kruskal-Wallis检验进行研究。适用时将使用箱线图表示。分析将使用R软件进行,显著性设定为p < 0.05。
本研究于2024年4月26日获得法国伦理委员会、CPP(保护人类委员会)东南II - 里昂 - 法国批准,参考编号2023 - 506936 - 34 - 00,主管当局ANSM(国家药品和健康产品安全局)于2024年5月17日批准该研究。本研究结果将发表在同行评审期刊上,并将在相关会议上展示。
NCT06497959;欧盟临床试验编号:2023 - 506936 - 34 - 00。